Request Demo
Last update 05 Dec 2025
Anti-CD30 CAR-T (Peking University)
Last update 05 Dec 2025
Overview
Basic Info
Drug Type Autologous CAR-T |
Synonyms- |
Target |
Action inhibitors |
Mechanism CD30 inhibitors(Tumor necrosis factor receptor superfamily member 8 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with Anti-CD30 CAR-T (Peking University)NCT02274584
Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Relapsed and Refractory CD30 Positive Lymphomas
100 Clinical Results associated with Anti-CD30 CAR-T (Peking University)
Login to view more data
100 Translational Medicine associated with Anti-CD30 CAR-T (Peking University)
Login to view more data
100 Patents (Medical) associated with Anti-CD30 CAR-T (Peking University)
Login to view more data
100 Deals associated with Anti-CD30 CAR-T (Peking University)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Anaplastic Large-Cell Lymphoma | Phase 2 | United States | 01 Mar 2014 | |
| Anaplastic Large-Cell Lymphoma | Phase 2 | China | 01 Mar 2014 | |
| CD19 Expressing Malignancies | Phase 2 | United States | 01 Mar 2014 | |
| CD19 Expressing Malignancies | Phase 2 | China | 01 Mar 2014 | |
| CD30 positive Non-Hodgkin Lymphoma | Phase 2 | United States | 01 Mar 2014 | |
| CD30 positive Non-Hodgkin Lymphoma | Phase 2 | China | 01 Mar 2014 | |
| CD30-Positive recurrent or refractory Cutaneous T-Cell Lymphoma | Phase 2 | United States | 01 Mar 2014 | |
| CD30-Positive recurrent or refractory Cutaneous T-Cell Lymphoma | Phase 2 | China | 01 Mar 2014 | |
| Hodgkin's Lymphoma | Phase 2 | United States | 01 Mar 2014 | |
| Hodgkin's Lymphoma | Phase 2 | China | 01 Mar 2014 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free